Tengion's interim CEO has high hopes for regenerative medicine

10/9/2011 | MedCityNews.com

Tim Bertram, Tengion's chief scientific officer and acting CEO, said that the time of regenerative medicine has come and that the technology will continue to thrive in coming years. At the Regenerative Medicine Roundtable, Bertram said companies should focus on the commercial applications of products in order to draw funding. Abner Mhashilkar, medical translational officer at the Wake Forest Institute for Regenerative Medicine who previously worked for venture capital firm Toucan Capital, said that funding was available for regenerative medicine firms but that most venture capitalists want to see a return on investment within six years.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA